Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2001
Business Overview: The Company operates in two primary segments: Animal Health Products and Research & Development (R&D). Its principal customers are in the U.S. dairy and beef industries, accounting for 78% of product sales in the current period. Key products include FIRST DEFENSE(R) and KAMAR(R) HEATMOUNT(R) DETECTOR.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenues | $1,488,678 | $1,447,020 |
| Net Profit After Taxes | $116,107 | $227,014 |
| Net Profit Per Share (Diluted) | $0.04 | $0.08 |
| Cash and Cash Equivalents | $1,918,841 | $2,103,020 (Ending Q1 2000) |
| Net Cash Provided by Operating Activities | $188,735 | $23,947 |
| Total Debt (Current + Long Term) | $429,577 | $434,659 (Dec 31, 2000) |
| Gross Margin (Product Sales) | 53% | 53% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by $42,000 (3%) to $1.49 million. Product sales rose 3% to $1.47 million, driven by a 5% increase in sales of FIRST DEFENSE and KAMAR HEATMOUNT DETECTOR.
- Profitability Decline: Net profit after taxes decreased by approximately 49% to $116,107. This decline is primarily attributed to a $77,063 non-cash tax expense recorded in Q1 2001, which was not present in the prior year.
- Operating Cash Flow: Net cash provided by operating activities improved significantly to $188,735 from $23,947 in the prior year, despite a $142,460 increase in inventory levels.
- Expense Increases: Sales and marketing expenses rose 17% to $320,765, and general and administrative expenses increased 11% to $132,815.
- Investing Activities: Net cash used for investing activities increased to $212,306 due to capital expenditures for facility expansion and manufacturing equipment.
Guidance, Outlook, and Risks
- Backlog and Capacity: The order backlog for FIRST DEFENSE increased from approximately $250,000 in March 2000 to $1,000,000 in March 2001. The Company is constructing a 5,300 sq. ft. facility addition (estimated cost $600,000) to increase production capacity, expected to be completed in Q2 2001.
- Licensing and Grants:
- Received a $50,000 payment in March 2001 from a technology license with Novatreat Ltd (Finland) for DiffGAM rights, with an additional $50,000 anticipated in 2001.
- Received a two-year grant of up to $400,000 from the Maine Technology Institute and two $70,000 grants from the USDA in April 2001 to fund clinical trials for MASTOUT(TM) and Johne's disease diagnostics.
- Outlook: Management believes it has sufficient capital resources to meet working capital requirements for the next twelve months. The Company anticipates continued profitable operations as funding requirements for animal health programs are lower than human health programs.
- Risks: Forward-looking statements are subject to risks including delays in regulatory approval, production difficulties, and competition. Sales of TIP-TEST(TM): JOHNE'S remain limited due to state regulatory barriers.
Investor Verification Checklist
- Tax Expense Impact: Verify the sustainability of profitability given the $77,000 non-cash tax expense in Q1 2001 and the utilization of net operating loss carryforwards.
- Backlog Conversion: Monitor the completion of the facility expansion and the ability to convert the $1,000,000 FIRST DEFENSE backlog into recognized revenue.
- Grant Repayment Terms: Review the repayment conditions for the Maine Technology Institute grant (up to $400,000 within two years of first commercial sale or 2% of sales).
- Inventory Build-up: Assess the $142,460 increase in inventory to ensure it aligns with the production ramp-up for the backlog and does not indicate obsolescence.
- Regulatory Hurdles: Track progress on overcoming state regulatory barriers for TIP-TEST(TM): JOHNE'S to evaluate future revenue diversification.